8-K current report · filed Nov 5, 2026

Korro Bio, Inc. (KRRO) 8-K Current Report: November 5, 2026

Item 1.02Item 2.02Item EX-99.1KRRO overview

Short answer

Korro Bio, Inc. (KRRO) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Novo Nordisk termination effective February 1, 2027, ending the collaboration after its 12-month hold period.

Korro Bio, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.02 · Termination of a Material Definitive Agreement

  • Novo Nordisk termination effective February 1, 2027, ending the collaboration after its 12-month hold period
  • Korro retains the $10.0 million upfront payment and faces no early termination penalties
  • No milestone payments were earned, eliminating potential future development and commercial payments
  • Licensed compounds and products return to Korro’s control, but collaboration-related research restrictions survive termination
  • Novo Nordisk will reimburse additional third-party wind-down and non-cancellable committed costs attributable to termination

Item 2.02 · Results of Operations and Financial Condition

  • Korro Bio announced financial results for the quarter ended September 30, 2026
  • Full quarterly results and management commentary appear in Exhibit 99.1, the accompanying press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 clinical execution: KRRO-121 dosing began in healthy volunteers, with UCD patient dosing targeted for first half 2027
  • KRRO-121 interim ANCHOR data targeted for second half 2027, creating the next major clinical catalyst
  • KRRO-111 preclinical results: >95% SERPINA1 editing, ~93% functional M-AAT, and ~95% pathogenic Z-AAT elimination
  • Cash, equivalents and marketable securities $124.8M, supporting operations into second half 2028
  • Q3 net loss $17.5M versus $18.1M, while collaboration revenue fell to $0 from $1.1M after the Novo Nordisk pause

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Korro Bio, Inc. 8-K filings

Get the next KRRO 8-K as it lands

Follow KRRO for push alerts, or ask the research agent what this filing means.